Role of MGMT and clinical applications in brain tumours;Rôle de la MGMT et implications cliniques dans les tumeurs cérébrales

Bulletin du Cancer

Volumn 94, Issue 9, 2007, Pages 769-773

  Paus, Christophe ^a   Murat, Anastasia ^a   Stupp, Roger ^a   Regli, Luca ^a   Hegi, Monika ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

Glioblastoma; Methylation; Methylguanine methyltransferase

Indexed keywords

6 O METHYLGUANINE; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; ALKYLATING AGENT; DNA METHYLTRANSFERASE; MGMT PROTEIN, HUMAN; POLYDEOXYRIBONUCLEOTIDE SYNTHASE; TUMOR PROTEIN; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG;

BIOPSY; BLOOD BRAIN BARRIER; BRAIN TUMOR; CANCER SURGERY; CLINICAL PRACTICE; DISEASE PREDISPOSITION; EPIGENETICS; GLIOBLASTOMA; HUMAN; METHYLATION; PATIENT IDENTIFICATION; POLYMERASE CHAIN REACTION; REVIEW; DNA METHYLATION; DRUG ANTAGONISM; DRUG EFFECT; DRUG RESISTANCE; ENZYMOLOGY; GENE SILENCING; GENE TARGETING; GENETICS; PHYSIOLOGY; PROMOTER REGION; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS, ALKYLATING; BRAIN NEOPLASMS; DNA METHYLATION; DNA MODIFICATION METHYLASES; DNA REPAIR ENZYMES; DRUG RESISTANCE, NEOPLASM; GENE SILENCING; GENE TARGETING; GLIOBLASTOMA; HUMANS; NEOPLASM PROTEINS; PROMOTER REGIONS (GENETICS); TREATMENT OUTCOME; TUMOR SUPPRESSOR PROTEINS;

EID: 35148833031     PISSN: 00074551     EISSN: 17696917     Source Type: Journal    
DOI: 10.1684/bdc.2007.0449     Document Type: Review

References (52)

1. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000 ; 100 : 57-70.
2. Hegi ME, Murat A, Lambiv WL, Stupp R. Brain tumors : molecular biology and targeted therapies. Ann Oncol 2006 ; 17(Suppl 10) : x191-xlx7.
3. Baylin SB, Ohm JE. Epigenetic gene silencing in cancer: a mechanism for early oncogenic pathway addiction? Nat Rev Cancer 2006 ; 6 : 107-16.
4. Esteller M, Corn PG, Baylin SB, Herman JG. A gene hypermethylation profile of human cancer. Cancer Res 2001 ; 61 : 3225-9.
5. Stupp R, Hegi ME, van den Bent MJ, Mason WP, Weller M, Mirimanoff RO, et al. Changing paradigms : an update on the multidisciplinary management of malignant glioma. Oncologist 2006 ; 11 : 165-80.
6. Gerson SL. MGMT : its role in cancer aetiology and cancer therapeutics. Nat Rev Cancer 2004 ; 4 : 296-307.
7. Ochs K, Kaina B. Apoptosis induced by DNA damage O6-methylguanine is Bcl-2 and caspase-9/3 regulated and Fas/caspase-8 independent. Cancer Res 2000 ; 60 : 5815-24.
8. Stojic L, Brun R, Jiricny J. Mismatch repair and DNA damage signalling. DNA Repair (Amst) 2004 ; 3 : 1091-101.
9. Dolan ME, Mitchell RB, Mummert C, Moschel RC, Pegg AE. Effect of O6-benzylguanine analogues on sensitivity of human tumor cells to the cytotoxic effects of alkylating agents. Cancer Res 1991 ; 51 : 3367-72.
10. Karran P. Mechanisms of tolerance to DNA damaging therapeutic drugs. Carcinogenesis 2001 ; 22 : 1931-7.
11. Stojic L, Cejka P, Jiricny J. High doses of SN1 type methylating agents activate DNA damage signaling cascades that are largely independent of mismatch repair. Cell Cycle 2005 ; 4 : 473-7 ; [Epub 2005 Mar 10].
12. Kesari S, Ramakrishna N, Sauvageot C, Stiles CD, Wen PY. Targeted molecular therapy of malignant gliomas. Curr Oncol Rep 2006 ; 8 : 58-70.
13. Watanabe K, Sato K, Biernat W, Tachibana O, von Ammon K, Ogata N, et al. Incidence and timing of p53 mutations during astrocytoma progression in patients with multiple biopsies. Clin Cancer Res 1997 ; 3 : 523-30.
14. Hermanson M, Funa K, Hartman M, Claesson-Welsh L, Heldin CH, Westermark B, et al. Platelet-derived growth factor and its receptors in human glioma tissue : expression of messenger RNA and protein suggests the presence of autocrine and paracrine loops. Cancer Res 1992 ; 52 : 3213-9.
15. Labuhn M, Jones G, Speel EJM, Maier D, Zweifel C, Gratzl O, et al. Quantitative real-time PCR does not show selective targeting of p14ARF at the INK4A locus but concomitant inactivation of both p16INK4A and p14ARF in 105 human primary gliomas. Oncogene 2001 ; 20 : 1103-9.
16. Lang FF, Miller DC, Koslow M, Newcomb EW. Pathways leading to glioblastoma multiforme : a molecular analysis of genetic alterations in 65 astrocytic tumors. J Neurosurg 1994 ; 81 : 427-36.
17. Tohma Y, Gratas C, Biernat W, Peraud A, Fukuda M, Yonekawa Y, et al. PTEN (MMAC1) Mutations are frequent in primary glioblastomas (de novo) but not in secondary glioblastomas. J Neuropathol Exp Neurol 1998 ; 57 : 684-9.
18. Von Deimling A, von Ammon K, Schoenfeld D, Wiestler OD, Seizinger BR, Louis DN. Subsets of glioblastoma multiforme defined by molecular genetic analysis. Brain Pathol 1993 ; 3 : 19-26.
19. Prigent SA, Nagane M, Lin H, Huvar I, Boss GR, Feramisco JR, et al. Enhanced tumorigenic behavior of glioblastoma cells expressing a truncated epidermal growth factor receptor is mediated through the Ras-Shc-Grb2 pathway. J Biol Chem 1996 ; 271 : 25639-45.
20. Prenzel N, Fischer OM, Streit S, Hart S, Ullrich A. The epidermal growth factor receptor family as a central element for cellular signal transduction and diversification. Endocr Relat Cancer 2001 ; 8 : 11-31.
21. Chakravarti A, Zhai G, Suzuki Y, Sarkesh S, Black PM, Muzikansky A, et al. The prognostic significance of phosphatidylinositol 3-kinase pathway activation in human gliomas. J Clin Oncol 2004 ; 22 : 1926-33.
22. Hegi ME, zur Hausen A, Rüedi D, Malin G, Kleihues P. Hemizygous or homozygous deletion of the chromosomal region containing the p16INK4a gene is associated with amplification of the EGF receptor gene in glioblastomas. Int J Cancer 1997 ; 73 : 57-63.
23. Hayashi Y, Ueki K, Waha A, Wiestler OD, von Deimling A. Association of EGFR gene amplification and CDKN2 (p16/MTS1) gene deletion in glioblastoma multiforme. Brain Pathol 1997 ; 7 : 871-5.
24. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn-MJB, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005 ; 352 : 987-96.
25. Denny BJ, Wheelhouse RT, Stevens MF, Tsang LL, Slack JA. NMR and molecular modeling investigation of the mechanism of activation of the antitumor drug temozolomide and its interaction with DNA. Biochemistry 1994 ; 33 : 9045-51.
26. Stupp R, Dietrich PY, Ostermann Kraljevic S, Pica A, Maillard I, Maeder P, et al. Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide. J Clin Oncol 2002 ; 20 : 1375-82.
27. Hegi ME, Diserens AC, Godard S, Dietrich PY, Regli L, Ostermann S, et al. Clinical trial substantiates the predictive value of MGMT-methylation in glioblastoma patients treated with temozolomide. Clin Cancer Res 2004 ; 10 : 1871-4.
28. Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 2005 ; 352 : 997-1003.
29. Esteller M, Garcia-Foncillas J, Andion E, Goodman SN, Hidalgo OF, Vanaclocha V, et al. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med 2000 ; 343 : 1350-4.
30. Esteller M, Hamilton SR, Burger PC, Baylin SB, Herman JG. Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia. Cancer Res 1999 ; 59 : 793-7.
31. Quinn JA, Desjardins A, Weingart J, Brem H, Dolan ME, Delaney SM, et al. Phase I trial of temozolomide plus O6-benzylguanine for patients with recurrent or progressive malignant glioma. J Clin Oncol 2005 ; 23 : 7178-87.
32. Cairncross JG, Ueki K, Zlatescu MC, Lisle DK, Finkelstein DM, Hammond RR, et al. Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst 1998 ; 90 : 1473-9.
33. Smith JS, Perry A, Borell TJ, Lee HK, O'Fallon J, Hosek SM, et al. Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytomas, and mixed oligoastrocytomas. J Clin Oncol 2000 ; 18 : 636-45.
34. Cairncross G, Berkey B, Shaw E, Jenkins R, Scheithauer B, Brachman D, et al. Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma : Intergroup Radiation Therapy Oncology Group Trial 9402. J Clin Oncol 2006 ; 24 : 2707-14.
35. Van den Bent MJ, Carpentier AF, Brandes AA, Sanson M, Taphoorn MJ, Bernsen HJ, et al. Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas : a randomized European Organisation for Research and Treatment of Cancer Phase III Trial. J Clin Oncol 2006 ; 24 : 2715-22.
36. Jenkins RB, Blair H, Ballman KV, Giannini C, Arusell RM, Law M, et al. A t(1;19)(q10;p10) Mediates the combined deletions of 1p and 19q and predicts a better prognosis of patients with oligodendroglioma. Cancer Res 2006 ; 66 : 9852-61.
37. Brandes AA, Tosoni A, Cavallo G, Reni M, Franceschi E, Bonaldi L, et al. Correlations between O6-methylguanine DNA methyltransferase promoter methylation status, 1p and 19q deletions, and response to temozolomide in anaplastic and recurrent oligodendroglioma : a prospective GICNO study. J Clin Oncol 2006 ; 24 : 4746-53.
38. Reifenberger J, Reifenberger G, Liu L, James CD, Wechsler W, Collins VP. Molecular genetic analysis of oligodendroglial tumors shows preferential allelic deletions on 19q and 1p. Am J Pathol 1994 ; 145 : 1175-90.
39. Reifenberger J, Reifenberger G, Ichimura K, Schmidt EE, Wechsler W, Collins VP. Epidermal growth factor receptor expression in oligodendroglial tumors. Am J Pathol 1996 ; 149 : 29-35.
40. Rich JN, Bigner DD. Development of novel targeted therapies in the treatment of malignant glioma. Nat Rev Drug Discov 2004 ; 3 : 430-46.
41. Wood JM, Bold G, Buchdunger E, Cozens R, Ferrari S, Frei J, et al. PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration. Cancer Res 2000 ; 60 : 2178-89.
42. Vredenburgh JJ, Desjardins A, Herndon JE, Quinn J, Rich J, Sathornsumetee S, et al. Bevacizumab, a monoclonal antibody to vascular endothelial growth factor (VEGF), and irinotecan for treatment of malignant gliomas. J Clin Oncol 2006 ; 24 : 59s (abstract #1506).
43. Herbst RS. Review of epidermal growth factor receptor biology. Int J Radiat Oncol Biol Phys 2004 ; 59(2 Suppl) : 21-6.
44. George D. Platelet-derived growth factor receptors : a therapeutic target in solid tumors. Semin Oncol 2001 ; 28(Suppl 17) : 27-33.
45. Rich JN, Reardon DA, Peery T, Dowell JM, Quinn JA, Penne KL, et al. Phase II trial of gefitinib in recurrent glioblastoma. J Clin Oncol 2004 ; 22 : 133-42.
46. Mellinghoff IK, Wang MY, Vivanco I, Haas-Kogan DA, Zhu S, Dia EQ, et al. Molecular detetminants of the response of glioblastomas to EGFR kinase inhibitors. N Engl J Med 2005 ; 353 : 2012-24.
47. Chakravarti A, Berkey B, Robins H, Guha A, Curran W, Brachman D, et al. An update of phase II results from RTOG 0211 : a phase I/II study of gefitinib with radiotherapy in newly diagnosed glioblastoma. J Clin Oncol 2006 ; 24(suppl) : 64s (abstract #1527).
48. Eskens FA, Dumez H, Hoekstta R, Perschl A, Brindley C, Bottcher S, et al. Phase I and pharmacokinetic study of continuous twice weekly intravenous administration of Cilengitide (EMD 121974), a novel inhibitor of the integrins alphavbeta3 and alphavbeta5 in patients with advanced solid tumours. Eur J Cancer 2003 ; 39 : 917-26.
49. Giglio P, Levin V. Cyclooxygenase-2 inhibitors in glioma therapy. Am J Ther 2004 ; 11 : 141-3.
50. Sminia P, Kuipers G, Geldof A, Lafleur V, Slotman B. COX-2 inhibitors act as radiosensitizer in tumor treatment. Biomed Pharmacother 2005 ; 59(Suppl 2) : S272-5.
51. Vecht CJ, Wagner GL, Wilms EB. Interactions between antiepileptic and chemotherapeutic drugs. Lancet Neurol 2003 ; 2 : 404-9.
52. Hegi ME, Stupp R. Correlative studies in neuro-oncology trials : should they influence treatment? Curr Oncol Rep 2006 ; 8 : 54-7.